# A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

> **NCT02212067** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 87 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** semaglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02212067
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-11
- **Primary completion:** 2015-05-11
- **Final completion:** 2015-05-11
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2018-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02212067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02212067, "A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02212067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*